BridgeBio Pharma, Inc.

Bristol-Myers Squibb Company (as described in Note 11) * * 80.6 %

The following table summarizes customers that represent 10% or greater of our consolidated revenue, net: Year ended December 31, 2024 2023 2022 (in thousands) Bayer Consumer Care AG (“Bayer”) 59.3% * * Kirin Co., Ltd (“Kyowa Kirin” or “KKC”) 34.3% * * Bristol-Myers Squibb Company ("BMS") * 80.6% 98.2% LianBio * 14.5% * * Represents less than 10% and/or not a customer in the applicable yearWe are subject to certain risks and uncertainties and we believe that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: ability to obtain future financing, regulatory approval and market acceptance of, and reimbursement for, product candidates, performance of third-party contract research organizations and manufacturers upon which we rely, development of sales channels, protection of our intellectual property, litigation or claims against us based on intellectual property, patent, product, regulatory, clinical or other factors, and our ability to attract and retain employees necessary to support our growth.We are dependent on third-party manufacturers to supply products for the commercial sale of Attruby and for research and development activities in our programs.

Kyowa Kirin Co., Ltd (as described in Note 11) * 34.3 % *

Kyowa Kirin Co., Ltd (as described in Note 11) * 75.0 % * 34.3 %

As of June 30, 2025 and December 31, 2024, our gross accounts receivable balance was comprised of payments primarily due from license and collaboration agreements with strategic partners and from product sales to customers.The following table summarizes customers that represent 10% or greater of our consolidated total gross revenues: Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Bayer (as described in Note 11) * 16.7% 30.1% 61.4% Kyowa Kirin Co., Ltd * 66.2% * 33.8% Alexion (as described in Note 11) 22.3% 14.7% 12.0% * Customer A 19.4% * 15.2% * Customer B 17.5% * 13.7% * Customer C 13.3% * * * Customer D 12.2% * 10.1% * * Represents less than 10% and/or not a customer in the applicable period.We are subject to credit risk from our accounts receivable.

As of March 31, 2025 and December 31, 2024, our gross accounts receivable balance was comprised of payments primarily due from license and collaboration agreements with strategic partners and from product sales to customers.The following table summarizes customers that represent 10% or greater of our consolidated total gross revenues: Three months ended March 31, 2025 2024 Bayer Consumer Care AG 59.6% 61.8% Customer A 10.6% * Kyowa Kirin Co., Ltd * 33.5% * Represents less than 10% and/or not a customer in the applicable period.We are subject to credit risk from our accounts receivable.

LianBio (as described in Note 6) * * 14.5 %